Burcu Kilic, research director for Public Citizen's Access to Medicines Program, discusses the complex web of COVID-19 intellectual property protection, and the new possibilities of emerging manufacturing capacity in the Global South.
K.M. Gopakumar, Senior Research and Legal Advisor at Third World Network, discusses the implications of the new patent vaccine waiver introduced in the WTO and how countries like India face political, technical, and policy constraints in accessing medicine.
Development economist, Jayati Ghosh, explains why more than a third of a million COVID-19 cases are being reported in India daily—and what that says about our world.
In the second interview as part of our new series, "Politics of Vaccine Equity: Conversations on the Frontline," public health consultant and lawyer, Rohit Malpani, discusses how since the HIV/AIDS pandemic there has been from a shift from politics to geopolitics, the new role that emerging economies play in the global landscape of COVID-19 vaccine access, and the importance of technology platforms.
In the first interview as part of our new series, "Politics of Vaccine Equity: Conversations on the Frontline," public health expert and senior policy advisor to the People's Vaccine Alliance, Mohga Kamal-Yanni, discusses how countries are at the whim of Big Pharma for supplying COVID-19 vaccines.
The Indian public health response to COVID-19 has been sidelining expert advice and scientific debate in favor of a political agenda, writes Dr. Rama Baru, professor at the Centre of Social Medicine and Community Health, Jawaharlal Nehru University.
Against the trend of vaccine nationalism, India is emerging as one of the major global suppliers of COVID-19 vaccines, writes Dr Biswajit Dhar, professor at the Centre for Economic Studies and Planning at Jawaharlal Nehru University.
